Related Experiment Video
Updated: Mar 22, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
28.0K
Tumor refractoriness to anti-VEGF therapy
1Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy.
Oncotarget
|April 16, 2016
Summary
Anti-angiogenic therapies targeting vascular endothelial growth factor (VEGF) show modest results due to resistance mechanisms. Re-evaluating strategies, including drug combinations and scheduling, is crucial for overcoming resistance and improving outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Vascular endothelial growth factor (VEGF) is critical for tumor angiogenesis and metastasis.
- Current anti-VEGF therapies offer limited clinical benefits, often leading to resistance.
Purpose of the Study:
- To analyze mechanisms of resistance to VEGF pathway inhibitors.
- To re-evaluate anti-angiogenic therapy strategies for improved efficacy.
Main Methods:
- Review and analysis of principal resistance mechanisms to VEGF inhibitors.
- Examination of factors contributing to treatment failure and metastasis.
Main Results:
- Resistance mechanisms include blood vessel normalization, hypoxia, inflammatory cell recruitment, alternative angiogenesis, and endothelial cell genomic instability.
- Clinical outcomes are often hampered by resistance, invasion, and metastasis.
Conclusions:
- Anti-angiogenic therapy concepts require re-evaluation.
- Rational drug combinations, optimized dosing, and scheduling are essential to overcome resistance and enhance anti-VEGF therapy effectiveness.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
02:56Treatment Resistent Cancers
1.5K
1.5K
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
02:38Mitogens and the Cell Cycle
8.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
02:07Tumor Progression
7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K